Guardant Health to Present Groundbreaking Precision Oncology Data at ESMO 2024
2 Sources
[1]
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types By Investing.com
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for
[2]
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in
Share
Copy Link
Guardant Health announces plans to share new data at ESMO 2024, showcasing the performance of its precision oncology technology across multiple advanced tumor types. The presentations will highlight the company's liquid biopsy tests and their potential impact on cancer treatment decisions.
Guardant Health's ESMO 2024 Presentations
Guardant Health, a leading precision oncology company, is set to present significant new data at the European Society for Medical Oncology (ESMO) Congress 2024. The company will showcase the performance of its cutting-edge precision oncology technology across various advanced tumor types, demonstrating its commitment to improving cancer care through innovative diagnostic solutions
1
.Key Highlights of the Presentations
The presentations will focus on Guardant Health's liquid biopsy tests, including the Guardant360® CDx and Guardant360 TissueNext™ tests. These tests are designed to provide comprehensive genomic profiling for patients with advanced cancers, offering valuable insights to inform treatment decisions
2
.Guardant360 CDx Test Performance
One of the key presentations will highlight the strong performance of the Guardant360 CDx test in detecting clinically relevant genomic alterations across multiple advanced solid tumor types. This data underscores the test's potential to guide treatment decisions for a wide range of cancer patients
1
.Guardant360 TissueNext Test Insights
Another presentation will focus on the Guardant360 TissueNext test, showcasing its ability to provide comprehensive genomic profiling results from small tissue samples. This capability is particularly crucial for patients with limited available tissue for testing, offering an alternative solution for genomic profiling
2
.Impact on Treatment Decisions
The data to be presented at ESMO 2024 will demonstrate how Guardant Health's precision oncology tests can significantly impact treatment decisions for patients with advanced cancers. By providing comprehensive genomic information, these tests enable oncologists to make more informed choices about targeted therapies and clinical trial eligibility
1
2
.Related Stories
Advancing Precision Medicine in Oncology
Guardant Health's presence at ESMO 2024 reinforces its position as a leader in the field of precision oncology. The company's ongoing research and development efforts aim to expand the utility of liquid biopsy tests and improve patient outcomes through personalized treatment approaches
2
.Future Implications
The data presented at ESMO 2024 is expected to have far-reaching implications for the field of oncology. As precision medicine continues to evolve, Guardant Health's technologies are poised to play a crucial role in shaping the future of cancer diagnosis and treatment, potentially leading to improved patient outcomes and more efficient use of healthcare resources
1
2
.References
Summarized by
Navi
Related Stories
Recent Highlights
1
OpenAI Pauses AI Model Training After Agents Hack Government Websites and Breach Security Protocols
Technology
2
Meta Unveils Camera-Free AI Glasses and Muse Integration Amid Privacy Debate at Connect 2026
Technology
3
AI Researchers Sound Alarm: Companies Racing Toward Self-Improving Systems Despite Existential Risks
Policy and Regulation
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
